Galmed Pharmaceuticals Stock Forecast, Price & News

+0.03 (+1.00 %)
(As of 06/23/2021 04:30 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume163,541 shs
Average Volume360,708 shs
Market Capitalization$76.00 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Galmed Pharmaceuticals logo

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.47 out of 5 stars

Medical Sector

641st out of 2,105 stocks

Pharmaceutical Preparations Industry

311th out of 832 stocks

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

Is Galmed Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Galmed Pharmaceuticals stock.
View analyst ratings for Galmed Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Galmed Pharmaceuticals?

Wall Street analysts have given Galmed Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Galmed Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Galmed Pharmaceuticals

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its quarterly earnings results on Thursday, May, 13th. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06.
View Galmed Pharmaceuticals' earnings history

How has Galmed Pharmaceuticals' stock been impacted by Coronavirus?

Galmed Pharmaceuticals' stock was trading at $4.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GLMD shares have decreased by 28.0% and is now trading at $3.03.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GLMD?

5 Wall Street analysts have issued 1 year target prices for Galmed Pharmaceuticals' stock. Their forecasts range from $14.00 to $33.00. On average, they expect Galmed Pharmaceuticals' share price to reach $22.00 in the next twelve months. This suggests a possible upside of 626.1% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:
  • Mr. Allen Baharaff, Co-Founder, Pres, CEO & Chairman (Age 56, Pay $766.58k)
  • Mr. Yohai Stenzler, Chief Financial Officer (Age 38, Pay $167.26k)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 36, Pay $167.54k)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 54, Pay $215.45k)
  • Dr. Tali Gorfine, Medical Consultant (Age 51, Pay $202.76k)
  • Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 38)

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (4.84%), Morgan Stanley (0.74%), Renaissance Technologies LLC (0.24%), Squarepoint Ops LLC (0.22%) and Goldman Sachs Group Inc. (0.11%).

Which major investors are selling Galmed Pharmaceuticals stock?

GLMD stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, and Renaissance Technologies LLC.

Which major investors are buying Galmed Pharmaceuticals stock?

GLMD stock was bought by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Goldman Sachs Group Inc., and Morgan Stanley.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $3.03.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals has a market capitalization of $76.00 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-28,770,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Galmed Pharmaceuticals have?

Galmed Pharmaceuticals employs 18 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is

Where are Galmed Pharmaceuticals' headquarters?

Galmed Pharmaceuticals is headquartered at 16 TIOMKIN STREET, TEL AVIV L3, 6578317.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.